Errant Gene Therapeutics Update: Tanzania, Court Appeals and More

Errant Gene Therapeutics Update Tanzania, Court Appeals and More

TrialSite News is, above all, dedicated to transparency and access to clinical trials with an emphasis on clinical research sites and investigators—those who are on the frontlines of clinical research. We bring to light the events and highlights of the clinical research—from translational research to clinical trials—that we believe patients and health professionals should know about. From life-saving therapies to unacceptable behaviors centering on greed and corruption, we cover it all. One such case of highly questionable practices came to our attention in the case of Errant Gene Therapeutics. We first covered them in our article, which has thousands of views, “A Familyman’s Battle Against the Forefront of Capitalist Medicine: The Case of Errant Gene Therapeutics.” We kept our audiences informed thereafter with “Follow-Up on Errant Gene Therapeutics: Their Major Victory in New York Court,” “Summaries of Errant Gene Therapeutics vs. Sloan Kettering Court Exhibits,” and finally, “Their Justice-Driven Road to Prosecution: Errant Gene Therapeutics vs. Third Rock Ventures.” 

Since then, TrialSite News has spoken with Patrick Girondi, founder and CEO of EGT, and thought it impo...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee